Terms: = Brain cancer AND NBN, AT-V2, 4683, ENSG00000104320, ATV, FLJ10155, NBS, AT-V1, MGC87362, NBS1 AND Diagnosis
11 results:
1. Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades.
Strauss KA; Williams KB; Carson VJ; Poskitt L; Bowser LE; Young M; Robinson DL; Hendrickson C; Beiler K; Taylor CM; Haas-Givler B; Hailey J; Chopko S; Puffenberger EG; Brigatti KW; Miller F; Morton DH
Mol Genet Metab; 2020 Nov; 131(3):325-340. PubMed ID: 33069577
[TBL] [Abstract] [Full Text] [Related]
2. Outcomes and prognostic factors in thyroid cancer patients with cranial metastases: A retrospective cohort study of 4,683 patients.
Hong YW; Lin JD; Yu MC; Hsu CC; Lin YS
Int J Surg; 2018 Jul; 55():182-187. PubMed ID: 29883619
[TBL] [Abstract] [Full Text] [Related]
3. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
[TBL] [Abstract] [Full Text] [Related]
4. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.
Wu G; Diaz AK; Paugh BS; Rankin SL; Ju B; Li Y; Zhu X; Qu C; Chen X; Zhang J; Easton J; Edmonson M; Ma X; Lu C; Nagahawatte P; Hedlund E; Rusch M; Pounds S; Lin T; Onar-Thomas A; Huether R; Kriwacki R; Parker M; Gupta P; Becksfort J; Wei L; Mulder HL; Boggs K; Vadodaria B; Yergeau D; Russell JC; Ochoa K; Fulton RS; Fulton LL; Jones C; Boop FA; Broniscer A; Wetmore C; Gajjar A; Ding L; Mardis ER; Wilson RK; Taylor MR; Downing JR; Ellison DW; Zhang J; Baker SJ
Nat Genet; 2014 May; 46(5):444-450. PubMed ID: 24705251
[TBL] [Abstract] [Full Text] [Related]
5. Ganglioglioma associated with alterations of nbn gene. A case report.
Grajkowska W; Piekutowska-Abramczuk D; Ciara E; Dembowska-Baginska B; Perek D; Roszkowski M; Daszkiewicz P; Matyja E; Pronicki M; Chrzanowska KH
Folia Neuropathol; 2009; 47(3):278-83. PubMed ID: 19813148
[TBL] [Abstract] [Full Text] [Related]
6. Useful markers for detecting minimal residual disease in cases of neuroblastoma.
Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Jun; 31(6):1071-4. PubMed ID: 18520032
[TBL] [Abstract] [Full Text] [Related]
7. Analyses of novel prognostic factors in neuroblastoma patients.
Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
Biol Pharm Bull; 2007 Dec; 30(12):2294-9. PubMed ID: 18057715
[TBL] [Abstract] [Full Text] [Related]
8. The first molecular details of ALT in human tumor cells.
Muntoni A; Reddel RR
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R191-6. PubMed ID: 16244317
[TBL] [Abstract] [Full Text] [Related]
9. Medulloblastoma with adverse reaction to radiation therapy in nijmegen breakage syndrome.
Bakhshi S; Cerosaletti KM; Concannon P; Bawle EV; Fontanesi J; Gatti RA; Bhambhani K
J Pediatr Hematol Oncol; 2003 Mar; 25(3):248-51. PubMed ID: 12621246
[TBL] [Abstract] [Full Text] [Related]
10. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
Cheung IY; Cheung NK
Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
[TBL] [Abstract] [Full Text] [Related]
11. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors.
Figarella-Branger DF; Durbec PL; Rougon GN
Cancer Res; 1990 Oct; 50(19):6364-70. PubMed ID: 2400996
[TBL] [Abstract] [Full Text] [Related]
